Obviously conviction is in place for platform and buying on the news anticipated from both conferences$$
EU and IACR conference data will blow away analyst.
dotsciencedailydotcom/releases/2014/03/140321164848dot adddddd htm here
I think CEO was in the EU last time I spoke with him. The conference call isn't an earnings call as you'd think. Rather, they are in the process of rolling out assays. And clinical data will be the driver of this ship, then reimbursement and finally, adopting of platform by docs. Continue upside in PPS can be anticipated as molecular testing gains traction in diagnostics/monitoring oncogene mutations.
Fill in dot with a real dot ...........................